Trial
NCT04361552
Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)
Phase IIIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Emory University
Collaborators
National Cancer Institute (NCI)
Condition
Cerebrovascular Accident
Intervention
Best Practice
Why stopped
Study abandoned due to drug billing issues
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-06-18